Research Only Cosmetic & Skin

Acetyl Hexapeptide-30

also known as: Inyline, Acetyl Hexapeptide-25 (former INCI)

Inyline — Lipotec's post-synaptic cosmetic peptide. Unlike Argireline-family pre-synaptic SNAP-25 mimetics or Vialox-style nAChR antagonists, Acetyl Hexapeptide-30 is claimed to block the agrin-MuSK interaction that maintains post-synaptic AChR clustering; was formerly INCI Acetyl Hexapeptide-25.

A synthetic acetylated hexapeptide developed by Lipotec (now Lubrizol) under the trade name Inyline® and later repositioned as Syntides™. The ingredient was originally registered as INCI Acetyl Hexapeptide-25; the INCI designation was subsequently updated to Acetyl Hexapeptide-30 (the two terms refer to the same Lipotec active). Mechanism is proposed as competitive antagonism of agrin at the muscle-specific kinase (MuSK) binding site on the post-synaptic membrane. This post-synaptic mechanism is distinct from the pre-synaptic SNAP-25 competitive inhibition of Argireline/SNAP-8 and from the nAChR antagonism of Vialox. Sequence and molecular formula are treated as proprietary by Lipotec. Cosmetic ingredient only; not a drug.

Mechanism of action

Proposed as a competitive antagonist of agrin at its binding site on muscle-specific kinase (MuSK), a transmembrane receptor tyrosine kinase on the post-synaptic membrane of the neuromuscular junction. In normal physiology, motor-neuron-secreted agrin binds MuSK via the LRP4 co-receptor, triggering MuSK autophosphorylation and downstream clustering of acetylcholine receptors at the post-synaptic membrane. Blocking this interaction is proposed to reduce post-synaptic responsiveness to acetylcholine and thereby reduce expression-muscle contractions. This mechanism sits alongside — and is marketed as complementary to — the pre-synaptic SNAP-25 inhibition of Argireline-class peptides and the nAChR antagonism of Vialox. Independent mechanistic replication outside Lipotec is minimal.

Primary uses

  • Topical cosmetic anti-aging formulations (expression-line reduction — post-synaptic mechanism)

Typical dosing

2–5 % (finished formulation, as supplied Inyline solution) twice daily (topical)

Cosmetic concentrations. Often combined with pre-synaptic (Argireline, SNAP-8) and nAChR-antagonist (Vialox) peptides.

Regulatory status

Cosmetic ingredient; not a drug. Current INCI name: Acetyl Hexapeptide-30 (formerly Acetyl Hexapeptide-25).

References

  1. [manufacturer] Lipotec / Lubrizol. "Inyline® peptide solution (Acetyl Hexapeptide-30) technical data sheet." Lipotec S.A.U., Gavà, Barcelona.
  2. [review] Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. "Cosmeceutical peptides in the framework of sustainable wellness economy." Front Chem, 2020;8:572923.
  3. [pubmed] Kim N, Stiegler AL, Cameron TO, et al. "Lrp4 is a receptor for Agrin and forms a complex with MuSK." Cell, 2008;135(2):334-342 (agrin/LRP4/MuSK mechanism).

Related peptides

Argireline

A cosmetic-industry hexapeptide marketed as "topical Botox" — reduces muscle contraction signaling at the neuromuscular junction; modest but documented effects on expression-line depth.

SNAP-8

An octapeptide cosmetic ingredient extending the Argireline concept — same SNAP-25 competitive mechanism with two additional residues and claims of enhanced activity.

Pentapeptide-3

Vialox — the "curare-mimetic" cosmetic peptide (GPRPA). Acts post-synaptically on peripheral nicotinic ACh receptors, unlike the pre-synaptic SNAP-25-mimetic Argireline class. Sometimes marketed as a snake-venom-inspired Botox alternative; efficacy data are primarily from the manufacturer.

Syn-Ake

A "snake-venom mimetic" cosmetic tripeptide modeled on Waglerin-1 (Tropidolaemus wagleri venom) — blocks post-synaptic acetylcholine receptors rather than acting pre-synaptically like Argireline; modest reductions in expression-line depth in manufacturer studies.

Leuphasyl

A cosmetic-ingredient pentapeptide modeled on leucine-enkephalin — marketed by Lipotec as a post-synaptic adjunct to Argireline-class pre-synaptic peptides for expression-line reduction.
Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.